Benitec grants license in Ambion settlement
Tuesday, 10 August, 2004
Benitec (ASX: BLT) has settled its patent infringement case against US company Ambion, giving the company a world-wide non-exclusive licence to make and sell DNA-directed RNAi products.
The suit, which was originally filed on March 22, 2004 in the US, was settled out of court. Details of the settlement and licence have not been released by the company.
The Ambion suit was first announced in March, along with two other lawsuits filed against Nucleonics and Genscript Corporation.
"We will continue to protect our issued RNAi patent estate whilst enabling the widest usage of this important technology for both research and commercial therapeutic purposes," said CEO John McKinley in a statement.
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
